The purpose of this study is to evaluate the safety and effectiveness of ION-682884 and determine if it can help people with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) which is a disease caused by change in a protein called transthyretin (TTR). ION-682884 is an investigational drug. "Investigational" means that ION-682884 is not yet approved for use in any settings outside of clinical research studies like this one and is considered experimental. ION-682884 has been shown to reduce the level of TTR in the blood of animals and healthy volunteers tested to date. Reducing the amount of TTR in your blood may reduce the amount of amyloid deposits in your body and may keep your cardiomyopathy from getting worse over time. However, it is not known if ION-682884 will help your cardiomyopathy.

If you meet the requirements and agree to participate in this study, you will receive subcutaneous (under the skin) injections of either ION-682884 or placebo once every 4 weeks from week 1 through week 137.
Your participation in this study will last up to 36 months and will consist of clinic visits and follow up visits at home.

The goal of this study is to understand how positive and negative social experiences affect epigenetic marks and gene function, and thereby influence lupus in African American women. This study requires one study visit to answer a few questionnaires and donate a blood sample. We are looking for volunteers with and without lupus to participate. Compensation is available.

The goal of this study is to understand the knowledge, views and perceptions from diverse communities, primarily from the Lowcountry, about the new field of personalized medicine (or precision health), and what factors might influence participation in precision health research studies. It is hoped that results from this study will help inform future strategies to increase the diversity of participants in precision health research.

Participation involves completion of a one-time survey that takes approximately 20 minutes to complete. Compensation is available.